Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret O’Donnell(City Of Hope National Medical Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Camille N. Abboud(Washington University in St. Louis), Jessica K. Altman, Frederick R. Appelbaum(Seattle Cancer Care Alliance), Daniel A. Arber(Stanford University), Vijaya Raj Bhatt(Susan Thompson Buffett Foundation), Dale L. Bixby(University of Michigan), William Blum(The Ohio State University), Steven Coutré(Stanford University), Marcos de Lima(Case Western Reserve University), Amir T. Fathi(Harvard University Press), Melanie Fiorella(University of California San Diego), James M. Foran(Cancer Institute (WIA)), Steven D. Gore(Yale Cancer Center), Aric C. Hall(University of Wisconsin–Madison), Patricia Kropf(Fox Chase Cancer Center), Jeffrey E. Lancet(University of South Florida), Lori J. Maness(Susan Thompson Buffett Foundation), Guido Marcucci(City Of Hope National Medical Center), Michael G. Martin(University of Tennessee Health Science Center), Joseph O. Moore(Cancer Institute (WIA)), Rebecca L. Olin(University of California, San Francisco), Deniz Peker(University of Alabama at Birmingham), Daniel A. Pollyea(University of Colorado Cancer Center), Keith W. Pratz(Cancer Institute (WIA)), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Paul J. Shami(University of Utah), Richard M. Stone(Dana-Farber Brigham Cancer Center), Stephen A. Strickland(Vanderbilt University), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Matthew J. Wieduwilt(University of California San Diego), Kristina M. Gregory(National Comprehensive Cancer Network), Ndiya Ogba(National Comprehensive Cancer Network)
Cited by 652Open Access
Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
Related Papers
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network|New England Journal of Medicine|2013|5.1k